Pyxis Oncology (PYXS) Free Cash Flow Growth (1y) (2021 - 2025)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,384,976.65 Bn | 1,384,976.64 Bn | - | 60.84% |
| 2 | Alterity Therapeutics | 777,208.84 Bn | 777,208.81 Bn | - | - |
| 3 | Legend Biotech | 2,801.00 Bn | 2,800.10 Bn | 242.10 Mn | 88.70% |
| 4 | Nanobiotix | 2,226.01 Bn | 2,225.95 Bn | - | - |
| 5 | Akari Therapeutics | 605.66 Bn | 605.66 Bn | - | -15.72% |
| 6 | Vertex Pharmaceuticals | 110.17 Bn | 102.92 Bn | 2.59 Bn | 66.37% |
| 7 | Regeneron Pharmaceuticals | 66.86 Bn | 58.11 Bn | 3.31 Bn | 3.98% |
| 8 | Evaxion A | 65.12 Bn | 65.10 Bn | - | - |
| 9 | Alnylam Pharmaceuticals | 39.94 Bn | 36.94 Bn | 959.66 Mn | 137.65% |
| 10 | Pyxis Oncology | 120.87 Mn | 103.97 Mn | 8.65 Mn | 45.95% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 45.95% |
| Sep 30, 2025 | 9.46% |
| Jun 30, 2025 | -474.09% |
| Mar 31, 2025 | -7.58% |
| Dec 31, 2024 | -26.46% |
| Sep 30, 2024 | 16.88% |
| Jun 30, 2024 | 77.37% |
| Mar 31, 2024 | 32.96% |
| Dec 31, 2023 | 25.61% |
| Sep 30, 2023 | 18.47% |
| Jun 30, 2023 | 44.26% |
| Mar 31, 2023 | -12.30% |
| Dec 31, 2022 | -68.51% |
| Sep 30, 2022 | -196.95% |
| Jun 30, 2022 | -1,057.09% |
| Mar 31, 2022 | -47.22% |
| Dec 31, 2021 | -610.81% |